The organizations that can take on 2-sided risk are usually bigger and that’s not always better for health care, said Jayson Slotnik, partner, Health Policy Strategies, Inc.
The organizations that can take on 2-sided risk are usually bigger and that’s not always better for health care, said Jayson Slotnik, partner, Health Policy Strategies, Inc.
Transcript
Do we need more organizations willing to take on downside risk in order to make real progress in transforming care delivery and realize substantial savings with value-based contracts?
So, value-based cancer care works in 1 of 2 ways. Either you've got 1-sided risk or you have 2-sided risk, right? That could be, either one could fit into a value-based contract. One-sided risk is just that, where one side is taking the risk, and usually there's not a lot of skin in the game on either side. CMS did this with something called the Oncology Care Model [OCM]. And it [produced] some savings, but after a while, quickly flattened out. However, on the other side is the 2-sided risk of value-based cancer care, which CMS tried to do through the OCM. It works somewhat, but again, didn't have a huge success.
At the end of the day, though, right, to take risk, you need to be big, you need to be large, you need to have sophisticated infrastructure to ascertain the risk, measure the risk, and understand where it's coming from and correct quickly. On one hand, that sounds great. On the other hand, my personal opinion: that that's actually bad for health care. Because what has occurred over the last, let's say, 10 years, ever since policies were put in place to incentivize double-sided, 2-sided risk vis-à-vis accountable care organizations, is that these organizations have gotten much bigger.
Hospitals have purchased lots of physicians’ offices in the community, the health payer has gone vertical, and you have 2 very large entities sitting down for a contract. And because they are each large, one can't live without the other. And so, there is actually an escalation in prices, certainly on the large provider side who says to the payer, “You can't have a health plan without me being in network. So here are my rates.” And that's where they start. And they don’t go right to a value-based contract. It takes a real stiffed back payer to push back and try to push it. We have not seen that yet. Because they haven't gotten that far. They have the flexibility of increasing premiums. And that's what's been done so far.
So, at the end of the day, do we need 2-sided [risk] in more organizations? Yes. Do they have to be bigger? I don't know that that's a success. Maybe what we need are more affordable tools for a smaller entity to be able to use, to equitize leverage with the health plan, in order to have a value-based contract without increasing premiums.
Health Equity & Access Weekly Roundup: January 11, 2025
January 11th 2025ACA enrollment rate hits a milestone, though IRA subsidies may not extend beyond 2025; network adequacy standards fail to translate into efficient access to mental health care for Medicaid enrollees; research examines racial disparities in postpartum hypertension and vaccine uptake.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
AI's Role in Oncology: Supporting, Not Replacing, Health Care Providers
January 9th 2025In this second half of our interview with Vanderbilt University Medical Center’s Travis Osterman, DO, MS, FAMIA, FASCO, he discusses opportunities for advancing the smart use of artificial intelligence (AI) in cancer care.
Read More
Real-World Discontinuations of Ocrelizumab in MS Comparable to Pivotal Trials
January 9th 2025Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in pivotal clinical trials among patients with different types of multiple sclerosis (MS).
Read More